Commission Regulation (EC) No 703/2007 of 21 June 2007 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Dihydrostreptomycin and Streptomycin (Text with EEA relevance)

22.6.2007 EN Official Journal of the European Union L 161/28
COMMISSION REGULATION (EC) No 703/2007
of 21 June 2007
amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Dihydrostreptomycin and Streptomycin
(Text with EEA relevance)
THE COMMISSION OF THE EUROPEAN COMMUNITIES
,
Having regard to the Treaty establishing the European Community,
Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (1), and in particular Article 2 thereof,
Having regard to the opinion of the European Medicines Agency formulated by the Committee for Medicinal Products for Veterinary Use,
Whereas:
(1) All pharmacologically active substances used in the Community in veterinary medicinal products intended for food-producing animals should be evaluated in accordance with Regulation (EEC) No 2377/90.
(2) The substance Dihydrostreptomycin is included in Annex I to Regulation (EEC) No 2377/90 for all ruminants for muscle, fat, liver, kidney and milk as well as for porcine for muscle, skin and fat, liver and kidney. Following examination of an application for the extension to rabbits of the existing entry for Dihydrostreptomycin, it is considered appropriate to modify the entry for Dihydrostreptomycin to include rabbits.
(3) The substance Streptomycin is included in Annex I to Regulation (EEC) No 2377/90 for bovine and ovine for muscle, fat, liver, kidney and milk as well as for porcine for muscle, skin and fat, liver and kidney. Following examination of the application for the extension to rabbits of the existing entry for Dihydrostreptomycin and taking account that the safety evaluation of the above referred two substances had been initially carried out together on the basis of their similarity in chemical structure and biological activity, it is also considered appropriate to modify the entry for Streptomycin to include rabbits for muscle, fat, liver and kidney. It was equally considered appropriate to modify the current entry of Streptomycin for bovine and ovine by a new entry for all ruminants for muscle, fat, liver, kidney and milk.
(4) Regulation (EEC) No 2377/90 should therefore be amended accordingly.
(5) An adequate period should be allowed before the applicability of this Regulation in order to enable Member States to make any adjustment which may be necessary in the light of this Regulation to the authorisations to place the veterinary medicinal products concerned on the market which have been granted in accordance with Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (2) to take account of the provisions of this Regulation.
(6) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,